US 340B Discount Restrictions By Pharma: HRSA Will Continue To ‘Walk The Walk’ In Opposition

Biden Administration officials pledge ongoing efforts to thwart manufacturer restrictions on 340B drug discounts, but at the same time urge hospitals to be more transparent about how they use the savings.

Can HRSA Get Anywhere Without Congressional Action? • Source: Shutterstock

More from Pricing Debate

More from Market Access